The purpose of this study is to identify a better tool for diagnosing patients with urinary infections and kidney stones when they come to the emergency room with abdominal or back pain (renal colic). This tool will help practitioners identify more easily if patients have a urinary infection along with a kidney stone. the primary objective is to predict accuracy of a new 4-point risk score which predicts a clinically significant UTI in patients presenting to the emergency department with obstructing kidney stones and concern for UTI requiring a ureteric stent or nephrostomy tube.THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential participants with 1 or more obstructive urinary tract calculi on CT scan in the emergency department and urology consultation for consideration of decompression (nephrostomy tube or ureteric stent) will be approached in the ER by the study team about study participation.

After breast augmentation or breast reconstruction with implants, some women experience a phenomenon called Breast Implant Illness which is a constellation of symptoms which include fatigue, joint pain, hair loss, brain fog, chronic pain, and a variety of other symptoms. Anecdotally, these women feel better after having their breast implants removed. The purpose of this study is to evaluate the women for symptom improvement one year after surgery or more by ways of a brief survey regarding their symptomatic improvement and the collection and analysis of blood samples.THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential participants will be contacted by the study personnel over the phone or in clinic at Meridian Plastic Surgeons by study personnel.

This randomized, open-label, parallel group, two-arm, multi-center assessment will compare IV BCV with IV CDV in adult and pediatric allogeneic HCT recipients with AdV viremia. A virologic response-driven approach to duration of treatment will be evaluated, in which randomized subjects are treated with either BCV or CDV until AdV viremia is confirmed as undetectable or until a maximum of 12 weeks of therapy, whichever occurs first. All subjects will be followed for a total of 24 weeks post-randomization, regardless of treatment assignment. Subjects will be assessed on a weekly basis through the end of treatment visit (EOT). Additional assessments will be performed at the test of cure (TOC) visit, which is 4 weeks after the last dose of study drug and at Weeks 12 and 24 post W1D1.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana University Simon Comprehensive Cancer Center (IUSCCC), please contact theIU Clinical Trials Office at Email: iutrials@iu.edu Phone: (317) 278-5632

This is a prospective, multi-center, single arm study focused on data and sample collection from participants diagnosed with Stage I to IV cancers and for whom standard of care Natera MRDtesting has been ordered (for example, SignateraTM, SignateraTM Genome, or LatitudeTM). This study will utilize study sites located within the United States of America (USA). The primary objective is to establish a comprehensive data repository to support the development and validation of cancer monitoring and detection tests.  The goal of this study is to clinically characterize biomarkers associated with development and validation of cancer monitoring and detection tests (“Natera cancer monitoring and detection test(s)”). The primary endpoint of this study is to obtain anonymized clinical data from up to 5,000 participants.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana University Simon Comprehensive Cancer Center (IUSCCC), please contact theIU Clinical Trials Office: Email: iutrials@iu.edu Phone: (317) 278-5632

The goal of this study is to evaluate current oral care practices in the NICU (completed with oral swab with either mother's breast milk or sterile water) and correlate with infant outcomes primarily related to immune responses with secondary investigation into neonatal rates of infection, growth parameters and length of stay in the NICU.THIS STUDY IS ENROLLING BY INVITATION ONLY - Eligible infants will be identified through daily screening of delivery logs, NICU admissions and obstetrician requests for NICU consult due to likely premature delivery. Parents or caregivers will be approached prior to delivery when feasible, or within 72 hours of birth. All research procedures will occur in the Riley Hospital for Children NICUs while infants are hospitalized.

This is a Double-blind, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy of Saroglitazar Magnesium 1 mg on normalization of ALP in patients having ALP > ULN to THIS STUDY IS ENROLLING BY INVITATION ONLY 

This phase III trial compares the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy versus dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (PH+) or ABL-class Philadelphia chromosome-like (Ph-Like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib and imatinib are in a class of medications called tyrosine kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib or imatinib in combination with standard chemotherapy may work better in treating patients with PH+ or Ph-Like ABL-class B-ALL compared to dasatinib or imatinib and chemotherapy alone.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632